Amgen Inc. shares rose 6% after the world's biggest biotechnology company said it acquired a prostate cancer drug that's in the final stages of human testing.
Amgen shares rose $4.13 to close at $74.63 on Nasdaq. Amgen announced the acquisition from closely held Praecis Pharmaceuticals Inc. of Cambridge, Mass., after Wednesday's close of U.S. stock markets.
